2005

Abrahams, E, Ginsburg, GS, and Silver, M (2005).
The Personalized Medicine Coalition: goals and strategies
.

Adams, KF, Patterson, JH, Gattis, WA, O'Connor, CM, Lee, CR, Schwartz, TA, and Gheorghiade, M (2005).
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis
.

ADVANCE, MI (2005).
Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial
.

Ahn, C and Jung, SH (2005).
Effect of dropouts on sample size estimates for test on trends across repeated measurements
.

Al, Kh (2005).
Does ICD therapy benefit women with a history of myocardial infarction and severe left ventricular dysfunction?
.

Al, Kh, Allen, La, Kramer, JM, Chen, AY, Hammill, BG, Delong, L, and Califf, RM (2005).
A survey of health care practitioners' knowledge of the QT interval
.

Al, Kh, Anstrom, KJ, Eisenstein, EL, Peterson, ED, Jollis, JG, Mark, DB, Li, Y, O'Connor, CM, Shaw, LK, and Califf, RM (2005).
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II
.

Al, Kh, Lucas, FL, Jollis, JG, Malenka, DJ, and Wennberg, DE (2005).
The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries
.

Al, Kh, Sanders, GD, Mark, DB, Lee, KL, Bardy, GH, Bigger, JT, Buxton, AE, Connolly, S, Kadish, A, Moss, A, Feldman, AM, Ellenbogen, KA, Singh, S, and Califf, RM (2005).
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004
.

Alexander, BD, Schell, WA, Miller, JL, Long, GD, and Perfect, JR (2005).
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole
.

Alexander, JH and Singh, KP (2005).
Inhibition of Factor Xa : a potential target for the development of new anticoagulants
.

Alexander, JH, Ferguson, TB, Joseph, DM, Mack, MJ, Wolf, RK, Gibson, CM, Gennevois, D, Lorenz, TJ, Harrington, RA, Peterson, ED, Lee, KL, Califf, RM, and Kouchoukos, NT (2005).
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics
.

Alexander, JH, Hafley, G, Harrington, RA, Peterson, ED, Ferguson, TB, Lorenz, TJ, Goyal, A, Gibson, M, Mack, MJ, Gennevois, D, Califf, RM, and Kouchoukos, NT (2005).
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
.

Alexander, JH, Yang, H, Becker, RC, Kodama, K, Goodman, S, Dyke, CK, Kleiman, NS, Hochman, JS, Berger, PB, Cohen, EA, Lincoff, AM, Burton, JR, Bovill, EG, Kawai, C, Armstrong, PW, and Harrington, RA (2005).
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial
.

Alexander, KP, Chen, AY, Roe, MT, Newby, LK, Gibson, CM, Allen, La, Pollack, C, Gibler, WB, Ohman, EM, and Peterson, ED (2005).
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes
.

Alexander, KP, Roe, MT, Chen, AY, Lytle, BL, Pollack, CV, Foody, JM, Boden, WE, Smith, SC, Gibler, WB, Ohman, EM, and Peterson, ED (2005).
Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative
.

Aljaroudi, WA, Halabi, AR, and Harrington, RA (2005).
Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future
.

Allen, AS and Barnhart, HX (2005).
General Marginal Regression Models for the Joint Modeling of Event Frequency and Correlated Severities with Applications to Clinical Trials
.

Allen, AS and Barnhart, HX (2005).
General marginal regression models for the joint modeling of event frequency and correlated severities with applications to clinical trials
.

Allen, AS and Satten, GA (2005).
Robust testing of haplotype/disease association
.

Allen, AS, Satten, GA, and Tsiatis, AA (2005).
Locally-efficient robust estimation of haplotype-disease association in family-based studies
.

Amos, A and Newby, LK (2005).
Using Biomarkers to Assess Risk and Consider Treatment Strategies in Non-ST-Segment Elevation Acute Coronary Syndromes
.

An, Y, Young, SP, Kishnani, PS, Millington, DS, Amalfitano, A, Corz, D, and Chen, YT (2005).
Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease
.

Anderson, DJ, Fangman, W, Fowler, VG, Corey, GR, and Sexton, DJ (2005).
A returning traveler with fever and rash
.

Anderson, DJ, Olaison, L, McDonald, JR, Miro, JM, Hoen, B, Selton-Suty, C, Doco-Lecompte, T, Abrutyn, E, Habib, G, Eykyn, S, Pappas, PA, Fowler, VG, Sexton, DJ, Almela, M, Corey, GR, and Cabell, CH (2005).
Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database
.